

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sisram Medical Ltd
復銳醫療科技有限公司*
(Incorporated in Israel with limited liability)
(Stock Code: 1696)

VOLUNTARY ANNOUNCEMENT

**PURCHASE OF SHARES IN THE COMPANY BY THE
CHIEF EXECUTIVE OFFICER AND EXECUTIVE DIRECTOR**

This announcement is made by Sisram Medical Ltd (the “**Company**”) on a voluntary basis.

The Company has been informed by Mr. Lior Moshe DAYAN (“**Mr. DAYAN**”), the Chief Executive Officer and an Executive Director of the Company, that on 11 July 2019, Mr. DAYAN made on-market purchases on The Stock Exchange of Hong Kong Limited of an aggregate of 77,500 shares in the Company (“**Shares**”) at a purchase price of HK\$3.979 per Share. As at 11 July 2019, Mr. DAYAN is interested in an aggregate of 113,500 Shares, representing approximately 0.026% of the issued share capital of the Company.

By Order of the Board
Sisram Medical Ltd
Yi LIU
Chairman

Hong Kong, 12 July 2019

As at the date of this announcement, the board of directors of the Company comprises Mr. Yi LIU, Mr. Lior Moshe DAYAN and Mr. Guojun BU as executive directors; Mr. Yifang WU, Mr. Yao WANG and Ms. Yang YANG as non-executive directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as independent non-executive directors.

** for identification purpose only*